Description générale
Bevacizumab is a monoclonal antibody that binds to vascular endothelial growth factor (VEGF) and inhibits angiogenesis. It is used in the treatment of vascular eye diseases and in treatment protocols for some cancers.
INN
Bevacizumab
Codes ATC
Type de médicament
Biological agent
Historique des statuts LME
Ajouté pour la première fois en 2013
(TRS
985)
pour
Age related macular degeneration
Wikipédia
DrugBank
Recommandations
Section
Ophthalmological preparations > Anti-vascular endothelial growth factor (VEGF) preparations
- Parenteral > Locoregional injections > Intravitreal: 25 mg per mL
Indications